Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Liminatus Pharma ( (LIMN) ) has shared an announcement.
On July 10, 2025, Liminatus Pharma, Inc. expanded its board of directors to six members by appointing Philip Lemons and Richard Baek as new directors. Philip Lemons, aged 54, brings over two decades of experience in clinical research and development, having held leadership roles in various global research institutions and consulting firms. Richard Baek, aged 33, offers expertise in financial oversight, internal controls, and regulatory compliance, with a background in finance roles across multiple sectors. These appointments are expected to enhance the company’s strategic direction and governance.
More about Liminatus Pharma
Average Trading Volume: 328,147
Technical Sentiment Signal: Sell
Current Market Cap: $135.8M
For detailed information about LIMN stock, go to TipRanks’ Stock Analysis page.